Boston Scientific Corporation (NYSE:BSX) Shares Sold by Ameritas Advisory Services LLC

Ameritas Advisory Services LLC reduced its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 57.2% in the first quarter, according to its most recent filing with the SEC. The fund owned 3,151 shares of the medical equipment provider's stock after selling 4,214 shares during the period. Ameritas Advisory Services LLC's holdings in Boston Scientific were worth $294,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Colonial Trust Co SC grew its stake in Boston Scientific by 1,625.0% in the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 260 shares in the last quarter. Investment Management Corp VA ADV purchased a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $25,000. Sunbeam Capital Management LLC bought a new position in Boston Scientific in the fourth quarter worth approximately $26,000. Ameriflex Group Inc. purchased a new position in Boston Scientific during the 4th quarter worth $31,000. Finally, Fairway Wealth LLC bought a new stake in Boston Scientific during the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In related news, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the sale, the senior vice president owned 36,193 shares of the company's stock, valued at approximately $3,441,592.37. The trade was a 11.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,347,824.96. The trade was a 24.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 461,970 shares of company stock worth $47,755,193 over the last quarter. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

Boston Scientific stock traded up $0.67 during mid-day trading on Friday, hitting $104.30. The company had a trading volume of 2,931,148 shares, compared to its average volume of 6,658,145. The company has a current ratio of 1.45, a quick ratio of 0.88 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $154.30 billion, a price-to-earnings ratio of 76.13, a P/E/G ratio of 2.69 and a beta of 0.68. The company's fifty day moving average is $103.37 and its 200-day moving average is $99.96. Boston Scientific Corporation has a 12-month low of $71.88 and a 12-month high of $107.53.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The firm's revenue was up 20.9% on a year-over-year basis. During the same quarter last year, the business earned $0.56 earnings per share. Equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BSX. Wall Street Zen raised Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Morgan Stanley raised their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. BTIG Research restated a "buy" rating and issued a $124.00 price target on shares of Boston Scientific in a report on Wednesday, April 23rd. Royal Bank Of Canada increased their price objective on shares of Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Finally, Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Twenty-two analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $116.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.